Solid Biosciences LLC Total Liabilities
Solid Biosciences LLC total liabilities. Based on the latest financial reports, Solid Biosciences LLC (SLDB) has total liabilities worth $46.51 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Solid Biosciences LLC liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Solid Biosciences LLC (2015–2025)
Total liabilities of Solid Biosciences LLC from 2015 to 2025. This chart illustrates how Solid Biosciences LLC's total liabilities have evolved over time, based on quarterly financial data.
Solid Biosciences LLC Competitors by Total Liabilities
The table below lists competitors of Solid Biosciences LLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tianjin Economic-technological Development Area Co Ltd
SHE:000652
|
China | CN¥35.63 Billion |
|
Zhejiang Truelove Vogue Co Ltd
SHE:003041
|
China | CN¥874.66 Million |
|
Sunyard System Engineering Co Ltd
SHG:600571
|
China | CN¥764.96 Million |
|
Wenzhou Hongfeng Electrical Alloy Co Ltd
SHE:300283
|
China | CN¥2.38 Billion |
|
Reitir fasteignafélag hf
IC:REITIR
|
Iceland | Ikr174.57 Billion |
|
Cognyte Software Ltd
NASDAQ:CGNT
|
USA | $304.69 Million |
|
Shanghai Smith Adhesive New
SHG:603683
|
China | CN¥1.55 Billion |
|
Henan Hengxing Science & Technology Co Ltd
SHE:002132
|
China | CN¥4.80 Billion |
Liability Composition Analysis (2015–2025)
This chart breaks down Solid Biosciences LLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Solid Biosciences LLC asset portfolio.
Liquidity & Leverage Metrics
Solid Biosciences LLC Total Liabilities Ratios Explained
Solid Biosciences LLC total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.82 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Solid Biosciences LLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Solid Biosciences LLC (2015–2025)
The table below shows the annual total liabilities of Solid Biosciences LLC from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $52.53 Million | +2.17% |
| 2024-12-31 | $51.42 Million | +33.69% |
| 2023-12-31 | $38.46 Million | -20.85% |
| 2022-12-31 | $48.59 Million | +101.03% |
| 2021-12-31 | $24.17 Million | -38.16% |
| 2020-12-31 | $39.08 Million | +66.86% |
| 2019-12-31 | $23.42 Million | +62.50% |
| 2018-12-31 | $14.41 Million | -89.36% |
| 2017-12-31 | $135.45 Million | +72.50% |
| 2016-12-31 | $78.52 Million | +3.84% |
| 2015-12-31 | $75.62 Million | -- |
About Solid Biosciences LLC
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachyca… Read more